5 -羟色胺能致幻剂作为COVID-19后综合征（或长COVID）的潜在治疗药物：综合综述

IF 5.3 2区医学 Q1 CLINICAL NEUROLOGY

Progress in Neuro-Psychopharmacology & Biological Psychiatry Pub Date : 2025-02-03 DOI:10.1016/j.pnpbp.2025.111279

Zhen Xuen Brandon Low , Shin Jie Yong , Hayam A. Alrasheed , Maha F. Al-Subaie , Nawal A. Al Kaabi , Mubarak Alfaresi , Hawra Albayat , Jawaher Alotaibi , Ali Al Bshabshe , Ameen S.S. Alwashmi , Amal A. Sabour , Maha A. Alshiekheid , Zainab H. Almansour , Huda Alharthi , Hani A. Al Ali , Adel A. Almoumen , Nabil A. Alqasimi , Hajir AlSaihati , Alfonso J. Rodriguez-Morales , Ali A. Rabaan

{"title":"5 -羟色胺能致幻剂作为COVID-19后综合征（或长COVID）的潜在治疗药物：综合综述","authors":"Zhen Xuen Brandon Low , Shin Jie Yong , Hayam A. Alrasheed , Maha F. Al-Subaie , Nawal A. Al Kaabi , Mubarak Alfaresi , Hawra Albayat , Jawaher Alotaibi , Ali Al Bshabshe , Ameen S.S. Alwashmi , Amal A. Sabour , Maha A. Alshiekheid , Zainab H. Almansour , Huda Alharthi , Hani A. Al Ali , Adel A. Almoumen , Nabil A. Alqasimi , Hajir AlSaihati , Alfonso J. Rodriguez-Morales , Ali A. Rabaan","doi":"10.1016/j.pnpbp.2025.111279","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale</h3><div>In our ongoing battle against the coronavirus 2019 (COVID-19) pandemic, a major challenge is the enduring symptoms that continue after acute infection. Also known as Long COVID, post-COVID-19 syndrome (PCS) often comes with debilitating symptoms like fatigue, disordered sleep, olfactory dysfunction, and cognitive issues (“brain fog”). Currently, there are no approved treatments for PCS. Recent research has uncovered that the severity of PCS is inversely linked to circulating serotonin levels, highlighting the potential of serotonin-modulating therapeutics for PCS. Therefore, we propose that serotonergic psychedelics, acting mainly via the 5-HT2A serotonin receptor, hold promise for treating PCS.</div></div><div><h3>Objectives</h3><div>Our review aims to elucidate potential mechanisms by which serotonergic psychedelics may alleviate the symptoms of PCS.</div></div><div><h3>Results</h3><div>Potential mechanisms through which serotonergic psychedelics may alleviate PCS symptoms are discussed, with emphasis on their effects on inflammation, neuroplasticity, and gastrointestinal function. Additionally, this review explores the potential of serotonergic psychedelics in mitigating endothelial dysfunction, a pivotal aspect of PCS pathophysiology implicated in organ dysfunction. This review also examines the potential role of serotonergic psychedelics in alleviating specific PCS symptoms, which include olfactory dysfunction, cognitive impairment, sleep disturbances, and mental health challenges.</div></div><div><h3>Conclusions</h3><div>Emerging evidence suggests that serotonergic psychedelics may alleviate PCS symptoms. However, further high-quality research is needed to thoroughly assess their safety and efficacy in treating patients with PCS.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"137 ","pages":"Article 111279"},"PeriodicalIF":5.3000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review\",\"authors\":\"Zhen Xuen Brandon Low , Shin Jie Yong , Hayam A. Alrasheed , Maha F. Al-Subaie , Nawal A. Al Kaabi , Mubarak Alfaresi , Hawra Albayat , Jawaher Alotaibi , Ali Al Bshabshe , Ameen S.S. Alwashmi , Amal A. Sabour , Maha A. Alshiekheid , Zainab H. Almansour , Huda Alharthi , Hani A. Al Ali , Adel A. Almoumen , Nabil A. Alqasimi , Hajir AlSaihati , Alfonso J. Rodriguez-Morales , Ali A. Rabaan\",\"doi\":\"10.1016/j.pnpbp.2025.111279\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Rationale</h3><div>In our ongoing battle against the coronavirus 2019 (COVID-19) pandemic, a major challenge is the enduring symptoms that continue after acute infection. Also known as Long COVID, post-COVID-19 syndrome (PCS) often comes with debilitating symptoms like fatigue, disordered sleep, olfactory dysfunction, and cognitive issues (“brain fog”). Currently, there are no approved treatments for PCS. Recent research has uncovered that the severity of PCS is inversely linked to circulating serotonin levels, highlighting the potential of serotonin-modulating therapeutics for PCS. Therefore, we propose that serotonergic psychedelics, acting mainly via the 5-HT2A serotonin receptor, hold promise for treating PCS.</div></div><div><h3>Objectives</h3><div>Our review aims to elucidate potential mechanisms by which serotonergic psychedelics may alleviate the symptoms of PCS.</div></div><div><h3>Results</h3><div>Potential mechanisms through which serotonergic psychedelics may alleviate PCS symptoms are discussed, with emphasis on their effects on inflammation, neuroplasticity, and gastrointestinal function. Additionally, this review explores the potential of serotonergic psychedelics in mitigating endothelial dysfunction, a pivotal aspect of PCS pathophysiology implicated in organ dysfunction. This review also examines the potential role of serotonergic psychedelics in alleviating specific PCS symptoms, which include olfactory dysfunction, cognitive impairment, sleep disturbances, and mental health challenges.</div></div><div><h3>Conclusions</h3><div>Emerging evidence suggests that serotonergic psychedelics may alleviate PCS symptoms. However, further high-quality research is needed to thoroughly assess their safety and efficacy in treating patients with PCS.</div></div>\",\"PeriodicalId\":54549,\"journal\":{\"name\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"volume\":\"137 \",\"pages\":\"Article 111279\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-02-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0278584625000338\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0278584625000338","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

理由：在我们与2019冠状病毒（COVID-19）大流行的持续斗争中，一个主要挑战是急性感染后持续存在的持久症状。COVID-19后综合征（PCS）也被称为长COVID，通常伴有疲劳、睡眠紊乱、嗅觉功能障碍和认知问题（“脑雾”）等衰弱症状。目前，还没有批准的治疗PCS的方法。最近的研究发现，PCS的严重程度与循环血清素水平呈负相关，突出了血清素调节治疗PCS的潜力。因此，我们提出，主要通过5-HT2A 5-羟色胺受体起作用的5-羟色胺能致幻剂有望治疗PCS。目的：本综述旨在阐明5 -羟色胺类致幻剂减轻PCS症状的潜在机制。结果：讨论了5 -羟色胺类致幻剂缓解PCS症状的潜在机制，重点讨论了其对炎症、神经可塑性和胃肠道功能的影响。此外，本综述探讨了血清素能致幻剂在减轻内皮功能障碍方面的潜力，内皮功能障碍是与器官功能障碍相关的PCS病理生理的关键方面。本综述还探讨了5 -羟色胺类致幻剂在缓解特定PCS症状中的潜在作用，包括嗅觉功能障碍、认知障碍、睡眠障碍和精神健康挑战。结论：新出现的证据表明，5 -羟色胺类致幻剂可能减轻PCS症状。然而，需要进一步的高质量研究来彻底评估它们治疗PCS患者的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review

Rationale

In our ongoing battle against the coronavirus 2019 (COVID-19) pandemic, a major challenge is the enduring symptoms that continue after acute infection. Also known as Long COVID, post-COVID-19 syndrome (PCS) often comes with debilitating symptoms like fatigue, disordered sleep, olfactory dysfunction, and cognitive issues (“brain fog”). Currently, there are no approved treatments for PCS. Recent research has uncovered that the severity of PCS is inversely linked to circulating serotonin levels, highlighting the potential of serotonin-modulating therapeutics for PCS. Therefore, we propose that serotonergic psychedelics, acting mainly via the 5-HT2A serotonin receptor, hold promise for treating PCS.

Objectives

Our review aims to elucidate potential mechanisms by which serotonergic psychedelics may alleviate the symptoms of PCS.

Results

Potential mechanisms through which serotonergic psychedelics may alleviate PCS symptoms are discussed, with emphasis on their effects on inflammation, neuroplasticity, and gastrointestinal function. Additionally, this review explores the potential of serotonergic psychedelics in mitigating endothelial dysfunction, a pivotal aspect of PCS pathophysiology implicated in organ dysfunction. This review also examines the potential role of serotonergic psychedelics in alleviating specific PCS symptoms, which include olfactory dysfunction, cognitive impairment, sleep disturbances, and mental health challenges.

Conclusions

Emerging evidence suggests that serotonergic psychedelics may alleviate PCS symptoms. However, further high-quality research is needed to thoroughly assess their safety and efficacy in treating patients with PCS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Neuro-Psychopharmacology & Biological Psychiatry 医学-精神病学

CiteScore

12.00

自引率

1.80%

发文量

153

审稿时长

56 days

期刊介绍： Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.